CS logo
small CS logo
Genesis Cancer Center - Silvis

Silvis, Illinois, United States
Cancer treatment center in Silvis, Illinois
801 Illini Dr, Silvis, IL 61282

About Genesis Cancer Center - Silvis


"The Genesis Cancer Care Institute helps patients beat cancer by using the next generation of cancer-fighting technology, and a focus on resources and support for the patient."
  • Top Sponsors
  • Top Collaborators
  • Trials By Phase
  • Recruitment Status
  • Top Conditions
  • Intervention Types
  • Top Intervention Names
  • Trials By Gender

Clinical Trials at Genesis Cancer Center - Silvis


During the past decade, Genesis Cancer Center - Silvis conducted 31 clinical trials. In the 10-year time frame, 31 clinical trials started and 4 clinical trials were completed, i.e. on average, 12.9% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 4 clinical trials were completed. i.e. 28.6% of trials that started reached the finish line.

Clinical Trials Sponsors and Collaborators


Out of the total clinical trials conducted in "Genesis Cancer Center - Silvis" #1 sponsor was "National Cancer Institute (NCI)" with 12 trials, followed by "Alliance for Clinical Trials in Oncology" with 7 trials sponsored, "SWOG Cancer Research Network" with 7 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 3 trials sponsored and "NRG Oncology" with 3 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Genesis Cancer Center - Silvis" #1 collaborator was "National Cancer Institute (NCI)" with 19 trials as a collaborator, "Canadian Cancer Trials Group" with 2 trials as a collaborator, "Bayer" with 1 trials as a collaborator, "Division of Cancer Control" with 1 trials as a collaborator and "NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP)" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

Clinical Trials Conditions at Genesis Cancer Center - Silvis


According to Clinical.Site data, the most researched conditions in "Genesis Cancer Center - Silvis" are "Invasive Breast Carcinoma" (5 trials), "Stage IV Lung Cancer AJCC v8" (5 trials), "Stage IVA Lung Cancer AJCC v8" (5 trials), "Stage IVB Lung Cancer AJCC v8" (5 trials) and "Recurrent Lung Non-Small Cell Carcinoma" (4 trials). Many other conditions were trialed in "Genesis Cancer Center - Silvis" in a lesser frequency.

Clinical Trials Intervention Types at Genesis Cancer Center - Silvis


Most popular intervention types in "Genesis Cancer Center - Silvis" are "Drug" (23 trials), "Other" (17 trials), "Biological" (11 trials), "Procedure" (10 trials) and "Radiation" (3 trials). Other intervention types were less common.
The name of intervention was led by "Biospecimen Collection" (8 trials), "Pembrolizumab" (7 trials), "Quality-of-Life Assessment" (7 trials), "Cisplatin" (6 trials) and "Computed Tomography" (6 trials). Other intervention names were less common.

Clinical Trials Genders at Genesis Cancer Center - Silvis


The vast majority of trials in "Genesis Cancer Center - Silvis" are 28 trials for "All" genders and 3 trials for "Female" genders.

Clinical Trials Status at Genesis Cancer Center - Silvis


Currently, there are NaN active trials in "Genesis Cancer Center - Silvis". undefined are not yet recruiting, 12 are recruiting, 16 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Genesis Cancer Center - Silvis, 1 suspended trials, and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Genesis Cancer Center - Silvis, 0 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".